Chronic Pain and the Opioid Epidemic: Wicked Issues Have No Simple Solutions
Written By Myra ChristopherMy mom was a steel magnolia (i.e., southern and perfectly charming), but she had a steel rod up her back. After her first surgery for stomach cancer at age 53, she refused pain medication because she said that she “could take it.” She was young and strong and committed to “beating cancer.” After nearly two years of chemotherapy, radiation and two more surgeries, the cancer won. Eventually, I watched her beg nurses to give her “a shot” minutes before another was scheduled and be told they were sorry but she would have to wait. I could tell by the expressions on their faces they truly were sorry.Calls of DesperationWhen the Center for Practical Bioethics began more than 30 years ago, I frequently had calls and letters from other family members telling me that an elderly loved one was dying in terrible pain and that the care team refused to give pain medication more often than scheduled or to increase the dose because they were told their loved one might become addicted and/or because a higher dose of morphine might affect the patient’s respiration and hasten death. · ICU nurses regularly reported calling physicians and pleading for orders to increase pain medication only to be told, “Absolutely no and do not call again!” · Physicians told me about patients who refused medication and suffered unnecessarily because they believe...
ConclusionsVitamin D insufficiency was prevalent in both newly diagnosed axSpA patients and healthy controls. There was no association between vitamin D and pain and disease activity in the newly diagnosed axSpA patients. Monitoring vitamin D levels is important and early intervention for vitamin D insufficiency is needed, especially in female patients.
Publication date: Available online 13 December 2019Source: Brain, Behavior, and ImmunityAuthor(s): N.B. Teixeira, M.B. Sant'Anna, A.C. Giardini, L.P. Araujo, L.A. Fonseca, A.S. Basso, Y. Cury, G. PicoloAbstractMultiple sclerosis (MS) is a Central Nervous System inflammatory demyelinating disease that has as primary symptoms losses of sensory and motor functions, including chronic pain. To date, however, few studies have investigated the mechanisms of chronic pain in animal models of MS since locomotor impairments render difficult its evaluation. It was previously demonstrated that in the MOG35-55-induced EAE, an animal mod...
Publication date: Available online 13 December 2019Source: Brain, Behavior, and ImmunityAuthor(s): F. Scott Hall, Dayanidhi Raman, Amit K. Tiwari
Among women with metastatic breast cancer, use of an investigational oral form of paclitaxel yielded a higher overall response rate than the IV form, but administration was unique and time-consuming.Medscape Medical News
Publication date: 14–20 December 2019Source: The Lancet, Volume 394, Issue 10215Author(s): Basu Dev Pandey, Anthony Costello
Publication date: 14–20 December 2019Source: The Lancet, Volume 394, Issue 10215Author(s): Mohammed A Mamun, Jannatul Mawa Misti, Mark D Griffiths, David Gozal
Publication date: 14–20 December 2019Source: The Lancet, Volume 394, Issue 10215Author(s): Virginia Berridge
Publication date: Available online 12 December 2019Source: The LancetAuthor(s): Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Simon Cawthorn, Robert E Mansel, Sibylle Loibl, Bernardo Bonanni, D Gareth Evans, Anthony Howell, IBIS-II investigatorsSummaryBackgroundTwo large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II]). Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo...
Mass abuse of the drug tramadol spans continents, from India to Africa to the Middle East. The problem is that advocates claimed it was a safer opioid, relieving pain with little risk of abuse
ConclusionThe present study reports a variant subgroup GII-a PEDV HM2017 strain in China and characterize its pathogenicity. PEDV strain HM2017 of subgroup GII-a presents a promising vaccine candidate for the control of PED outbreaks in China.
More News: Addiction | Babies | Babies Heart Conditions | Back Pain | Blogging | Bone Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cancer in Adolescents | Cardiology | Chemotherapy | Children | Chronic Pain | Dentistry | Epidemics | Epidemiology | Eyes | Fentanyl | Gastric (Stomach) Cancer | Haemophilia | Health Management | Health Medicine & Bioethics Commentators | Heart | Hemophilia | Insurance | Insurers | International Medicine & Public Health | Morphine | Nurses | Nursing | Oral Cancer | Overdose | Oxycodone | OxyContin | Pain | Pain Management | Percocet | Sickle Cell Anemia | Study | Training | Universities & Medical Training